Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Walden Biosciences Launches with $51M Series A

2020-10-07
CAMBRIDGE, MA, Walden Biosciences announced its launch with a $51 million Series A financing led by ARCH Venture Partners and UCB Ventures.
Walden Biosciences, a biotechnology company focused on transforming the treatment of kidney disease, announced its launch with a $51 million Series A financing led by ARCH Venture Partners and UCB Ventures. Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function.

Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease. Walden was launched in 2020 by ARCH Venture Partners and UCB Ventures and is headquartered in Cambridge, MA.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors